









Markets
/
Stocks
/
nasdaq-sny
/

Sanofi SA

SNY

50.940USD

+0.260+0.51%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

124.00BMarket Cap

12.11P/E TTM



Sanofi SA

50.940

+0.260+0.51%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sanofi SA

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sanofi SA's Score

Industry at a Glance

Industry Ranking

47 / 160

Overall Ranking

125 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

62.574

Target Price

+22.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sanofi SA Highlights

StrengthsRisks

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.

Undervalued

The company’s latest PE is 12.26, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 249.99M shares, decreasing 10.55% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 71.72M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.63, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 15.39B, representing a year-over-year decrease of 1.03%, while its net profit experienced a year-over-year decrease of 5.89%.

Score

Industry at a Glance

Previous score

8.63

Change



Financials

8.67

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.68

Key Metrics

Free cash flow

No Data

Sanofi SA's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 5.82, which is lower than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is 12.26, which is 161.88% below the recent high of 32.11 and 8.86% above the recent low of 11.18.

Score

Industry at a Glance

Previous score

5.82

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.20, which is higher than the Pharmaceuticals industry's average of 7.79. The average price target for Sanofi SA is 60.62, with a high of 74.67 and a low of 56.00.

Score

Industry at a Glance

Previous score

8.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

62.574

Target Price

+23.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Sanofi SA

SNY

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 8.88, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 52.64 and the support level at 48.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.02

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.215

Buy

RSI(14)

58.536

Neutral

STOCH(KDJ)(9,3,3)

55.351

Neutral

ATR(14)

0.952

High Vlolatility

CCI(14)

72.426

Neutral

Williams %R

31.980

Buy

TRIX(12,20)

0.246

Sell

StochRSI(14)

20.172

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

51.146

Sell

MA10

50.525

Buy

MA20

49.888

Buy

MA50

48.730

Buy

MA100

48.685

Buy

MA200

51.058

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 10.27%, representing a quarter-over-quarter decrease of 5.43%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 71.72M shares, representing 2.95% of shares outstanding, with 1.05% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

71.72M

-2.01%

Fisher Investments

Star Investors

13.14M

-3.18%

Invesco Advisers, Inc.

8.56M

-24.69%

Capital World Investors

8.35M

+0.36%

Managed Account Advisors LLC

7.48M

-1.16%

Barrow Hanley Global Investors

Star Investors

7.28M

-0.94%

T. Rowe Price Associates, Inc.

Star Investors

5.52M

-49.93%

Wellington Management Company, LLP

4.33M

-2.18%

Putnam Investment Management, L.L.C.

4.13M

+10.97%

Boston Partners

3.99M

-2.45%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 7.88, which is higher than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.